C9 and amyotrophic lateral sclerosis: However, the findings that the levels of dipeptide repeat appear to be stable over time and decrease after ASO therapy in cellular and animal models of C9-ALS [92] have made it a serious candidate for a pharmacodynamic biomarker in C9-ALS.